FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/06/2025
Voltar para busca
Dado oficial do USPTO
INOVIQ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 42
Data de depósito
20/05/2022
Data de registro
17/12/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/12/2024
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
AU
Examinador
BRUNDAGE, DAVID WILLIAM
Unidade examinadora
M30
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
INOVIQ Limited
Representantes
Charles G. Zug Nelson Mullins Riley & Scarborough LLP
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticalbiotechnology and medical preparations and substances for the preventiondiagnosis or treatment of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases; pharmaceuticalbiotechnology and medical preparations and substances for the treatmentreconstruction and repair of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical diagnostic useextracellular vesiclesRNAprotein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatmentreconstruction and repair of cancerneurodegenerativecardiovascularinflammatorymetabolic diseases using antibodies; immunological antibodies for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicineextracellular vesiclesRNAprotein arrays or monoclonal antibodies; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparationsreagentspharmaceutical and biochemical anti-cancer substancesproducts for the preventiondiagnosis or treatment of cancerneurodegenerativeinflammatorymetabolic diseasestesting materialsdiagnostic test stripsimmunoassaysPCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposesdiagnostic biomarker reagents; reagents for use in diagnostic tests for medical purposes; reagents for medical diagnosis; proteins for use in recombinant DNA technology for medical diagnosis purposes; proteinsnamely protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes
Classe 10
Biotechnology medical apparatus for the preventiondiagnosis or treatment of cancerneurodegenerativeinflammatorymetabolic diseases; biotechnology medical apparatusmedical apparatus for the capture of extracellular vesicles; medical diagnostic apparatus and instruments for testing biofluidsplasmaserumsalivaurine and cell cultures for sale in kit form
Classe 42
Scientific researchclinical researchdevelopmentadvisory and consultancy services in relation to antibody production; vaccine screeningin the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research; advisory services relating to diagnostic products for scientific researchnamely development of diagnostic products for scientific researchextracellular vesical (EV) isolationscreating custom NET buildsdeveloping diagnostic assays; computer-aided diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposesresearch services relating to diagnostic products for scientific researchextracellular vesical (EV) isolationscreating custom NET buildsdeveloping diagnostic assays; research services in the field of diagnostic preparations; preparation of reports relating to medicalscientific and technical research; provision of information relating to medicalscientific and technical research; research and development of products; research and development of products in the field of antibody generation; research and development of productsnew therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of productsextracellular vesicle-based diagnostic productsextracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistrybiochemistrymedicinal chemistrydrug developmentbiotechnologymicrobiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; scientific laboratory research and analysis services for research and analysis of new productsextracellular vesicle-based diagnostic productsextracellular vesicle-based therapeutic products; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell lineculturing of cells for others for scientific research purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
19/05/2025
FIMP
FINAL DISPOSITION PROCESSED
19/05/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/03/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/12/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
17/12/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
15/10/2024
PUBO
PUBLISHED FOR OPPOSITION
15/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
25/09/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/09/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
11/09/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/09/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
11/09/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/09/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/08/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/08/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/08/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
11/03/2024
RFNT
REFUSAL PROCESSED BY IB
26/02/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
21/02/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
21/02/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/02/2024
RFRR
REFUSAL PROCESSED BY MPU
07/02/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
22/03/2023
CNRT
NON-FINAL ACTION WRITTEN
21/03/2023
DOCK
ASSIGNED TO EXAMINER
10/03/2023
MAFR
APPLICATION FILING RECEIPT MAILED
24/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/09/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
16/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace INOVIQ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.